Sector Gamma AS lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 34.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,900 shares of the biopharmaceutical company’s stock after acquiring an additional 25,000 shares during the quarter. Alnylam Pharmaceuticals accounts for approximately 1.3% of Sector Gamma AS’s investment portfolio, making the stock its 28th largest holding. Sector Gamma AS owned approximately 0.09% of Alnylam Pharmaceuticals worth $7,793,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Capital Investment Advisory Services LLC bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at about $25,000. City Holding Co. purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at about $30,000. CWM LLC grew its stake in Alnylam Pharmaceuticals by 1,571.4% in the third quarter. CWM LLC now owns 585 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 550 shares during the last quarter. US Bancorp DE grew its stake in Alnylam Pharmaceuticals by 70.2% in the second quarter. US Bancorp DE now owns 628 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 259 shares during the last quarter. Finally, Price Wealth Management Inc. purchased a new position in Alnylam Pharmaceuticals in the second quarter valued at about $46,000. Hedge funds and other institutional investors own 93.95% of the company’s stock.
Several equities analysts have issued reports on the company. Zacks Investment Research lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $93.00 target price on the stock. in a research note on Wednesday, September 18th. Stifel Nicolaus set a $116.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Cowen cut their target price on Alnylam Pharmaceuticals from $147.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Barclays reiterated a “buy” rating and issued a $125.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, August 7th. Finally, ValuEngine lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $111.59.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.92) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.17) by $0.25. Alnylam Pharmaceuticals had a negative return on equity of 52.88% and a negative net margin of 485.73%. The firm had revenue of $70.06 million during the quarter, compared to analysts’ expectations of $57.14 million. During the same period in the previous year, the business earned ($1.56) earnings per share. The firm’s revenue for the quarter was up 3284.5% on a year-over-year basis. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.89 EPS for the current fiscal year.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 58,913 shares of the company’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $89.99, for a total value of $5,301,580.87. Following the completion of the sale, the president now directly owns 111,851 shares in the company, valued at approximately $10,065,471.49. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO John Maraganore sold 49,456 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $79.45, for a total value of $3,929,279.20. Following the completion of the sale, the chief executive officer now owns 239,449 shares of the company’s stock, valued at $19,024,223.05. The disclosure for this sale can be found here. 3.60% of the stock is currently owned by insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Featured Story: What are the Different Types of Leveraged Buyouts?
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.